AstraZeneca PLC
LSE:AZN
EV/S
Enterprise Value to Sales
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
Market Cap | EV/S | ||||
---|---|---|---|---|---|
UK |
AstraZeneca PLC
LSE:AZN
|
185.8B GBP | 43.9 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733.3 | |
US |
Eli Lilly and Co
NYSE:LLY
|
696.4B USD | 20.9 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 17 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.8 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 255 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
351.8B USD | 4.4 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.2B USD | 6 | ||
CH |
Novartis AG
SIX:NOVN
|
182.9B CHF | 4.4 | ||
CH |
Roche Holding AG
SIX:ROG
|
176.2B CHF | 3.3 | ||
US |
Pfizer Inc
NYSE:PFE
|
143.4B USD | 3.4 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.